Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
Steensma
David P
DP
Mayo Clinic, Rochester, MN 55905, USA. steensma.david@mayo.edu
D000368:Aged; D002986:Clinical Trials as Topic; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000191:economics; D006397:Hematinics / Q000009:adverse effects* / Q000191:economics; D006801:Humans; D054524:Medicare Part D / Q000191:economics / Q000331:legislation & jurisprudence*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011994:Recombinant Proteins; D014481:United States
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa